Collaborative

 

Analyst coverage

Institute
Analyst
Target price
Report
Intron Health Research
Dominic Rose
47 CHF
view
Baader Bank
Amandeep Goyal
81 CHF
view
Stifel
Daniel Jelovcan
68 CHF
view

News

Press Releases

19.12.24
Xlife Sciences AG Publishes 2023 ESG Report: A Continued Commitment to Sustainable Innovation
28.6.24
Xlife Sciences AG: Successful General Assembly and New Trading Hours on the Sparks Segment of SIX
26.6.24
Xlife Sciences AG Reports Success in Liver Diagnostics – x-nuclear diagnostics GmbH Achieves Market Readiness
Archive

Ad hoc News

9.5.2022
Xlife Sciences: First Valuation Report confirms substancial potential of the project portfolio and assumes CHF 574 million in the most conservative scenario
29.4.2022
Annual Report 2021 (only available in german)
25.4.2022
License partner of Xlife Sciences announces successful completion of phase 1 of in-vivo trial for ATROSIMAB – out-licensing of the compound intended
Archive

Downloads

Financial Reports

September 19, 2024
Half-Year Report 2024
April 30, 2024
Valuation Report 2023
April 23, 2024
Annual Report 2023
September 21, 2023
Half-Year Report 2023
April 27, 2023
Valuation Report 2022
April 20, 2023
Annual Report 2022
September 28, 2022
Half-Year Report 2022
May 9, 2022
Valuation Report 2021
April 29, 2022
Annual Report 2021
February 8, 2022
Interim financial statement Q3 2021 (only in german)
August 5, 2021
Semi-Annual Report 2021
Half-year results (only available in German)
May 29, 2020
Annual statement 2020

Sign up for our media releases